首页 > 最新文献

Neurological Research and Practice最新文献

英文 中文
EXERTION: a pilot trial on the effect of aerobic, smartwatch-controlled exercise on stroke recovery: effects on motor function, structural repair, cognition, mental well-being, and the immune system. 运动:一项关于有氧、智能手表控制的运动对中风恢复影响的试点试验:对运动功能、结构修复、认知、心理健康和免疫系统的影响。
Pub Date : 2023-05-11 DOI: 10.1186/s42466-023-00244-w
Frederike A Straeten, Stephanie van Zyl, Bastian Maus, Jochen Bauer, Heiner Raum, Catharina C Gross, Sabine Bruchmann, Nils C Landmeyer, Cornelius Faber, Jens Minnerup, Antje Schmidt-Pogoda

Introduction: Motor impairments are the objectively most striking sequelae after stroke, but non-motor consequences represent a high burden for stroke survivors as well. Depression is reported in one third of patients, the fatigue prevalence ranges from 23 to 75% due to heterogenous definitions and assessments. Cognitive impairment is found in one third of stroke patients 3-12 months after stroke and the risk for dementia is doubled by the event. Aerobic exercise has been shown to reduce depressive symptoms, counteract fatigue, and improve cognitive functions in non-stroke patients. Furthermore, exercise is known to strengthen the immune system. It is unknown, though, if aerobic exercise can counteract poststroke depression, fatigue, poststroke dementia and poststroke immunosuppression. Therefore, we aim to analyse the effect of aerobic exercise on functional recovery, cognition, emotional well-being, and the immune system. Reorganization of topological networks of the brain shall be visualized by diffusion MRI fibre tracking.

Methods: Adults with mild to moderate stroke impairment (initial NIHSS or NIHSS determined at the moment of maximal deterioration 1-18) are recruited within two weeks of stroke onset. Study participants must be able to walk independently without risk of falling. All patients are equipped with wearable devices (smartwatches) measuring the heart rate and daily step count. The optimal heart rate zone is determined by lactate ergometry at baseline. Patients are randomized to the control or the intervention group, the latter performing a heart rate-controlled walking training on own initiative 5 times a week for 45 min. All patients receive medical care and stroke rehabilitation to the usual standard of care. The following assessments are conducted at baseline and after 90 days: Fugl Meyer-assessment for the upper and lower extremity, 6 min-walk test, neuropsychological assessment (cognition: MoCA, SDMT; fatigue and depression: FSMC, HADS-D, participation: WHODAS 2.0 12-items), blood testing (i.e. immune profiling to obtain insights into phenotype and functional features of distinct immune-cell subsets) and cranial magnetic resonance imaging (MRI) with grid-sampled diffusion weighted imaging, white matter fibre tracking and MR spectroscopy.

Perspective: This study investigates the effect of smartwatch-controlled aerobic exercise on functional recovery, cognition, emotional well-being, the immune system, and neuronal network reorganization in stroke patients. Trial registration ClinicalTrials.gov NCT Number: NCT05690165. First posted19 January 2023. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT05690165.

运动障碍是卒中后最显著的后遗症,但非运动后果对卒中幸存者来说也是一个沉重的负担。据报道,三分之一的患者患有抑郁症,由于定义和评估不同,疲劳患病率从23%到75%不等。三分之一的中风患者在中风后3-12个月出现认知障碍,患痴呆症的风险增加一倍。有氧运动已被证明可以减轻抑郁症状,抵消疲劳,并改善非中风患者的认知功能。此外,众所周知,锻炼可以增强免疫系统。然而,目前尚不清楚有氧运动是否能抵消中风后抑郁、疲劳、中风后痴呆和中风后免疫抑制。因此,我们的目的是分析有氧运动对功能恢复、认知、情绪健康和免疫系统的影响。大脑拓扑网络的重组应通过扩散MRI纤维跟踪可视化。方法:在卒中发作两周内招募有轻度至中度卒中损害的成人(初始NIHSS或NIHSS在最大恶化时刻1-18确定)。研究参与者必须能够独立行走,没有摔倒的风险。所有患者都配备了可穿戴设备(智能手表)来测量心率和每日步数。最佳心率区域由基线时的乳酸几何值决定。患者被随机分为对照组和干预组,干预组每周自主进行心率控制步行训练5次,每次45分钟。所有患者均接受常规标准护理的医疗护理和中风康复。在基线和90天后进行以下评估:Fugl meyer -上肢和下肢评估,6分钟步行测试,神经心理评估(认知:MoCA, SDMT;疲劳和抑郁:FSMC, HADS-D,参与:WHODAS 2.0 12项),血液检测(即免疫谱分析,以了解不同免疫细胞亚群的表型和功能特征)和采用网格采样扩散加权成像的颅磁共振成像(MRI),白质纤维跟踪和MR光谱。视角:本研究探讨智能手表控制的有氧运动对脑卒中患者功能恢复、认知、情绪健康、免疫系统和神经网络重组的影响。临床试验注册ClinicalTrials.gov NCT编号:NCT05690165。首次发布于2023年1月19日。追溯登记,https://clinicaltrials.gov/ct2/show/NCT05690165。
{"title":"EXERTION: a pilot trial on the effect of aerobic, smartwatch-controlled exercise on stroke recovery: effects on motor function, structural repair, cognition, mental well-being, and the immune system.","authors":"Frederike A Straeten,&nbsp;Stephanie van Zyl,&nbsp;Bastian Maus,&nbsp;Jochen Bauer,&nbsp;Heiner Raum,&nbsp;Catharina C Gross,&nbsp;Sabine Bruchmann,&nbsp;Nils C Landmeyer,&nbsp;Cornelius Faber,&nbsp;Jens Minnerup,&nbsp;Antje Schmidt-Pogoda","doi":"10.1186/s42466-023-00244-w","DOIUrl":"https://doi.org/10.1186/s42466-023-00244-w","url":null,"abstract":"<p><strong>Introduction: </strong>Motor impairments are the objectively most striking sequelae after stroke, but non-motor consequences represent a high burden for stroke survivors as well. Depression is reported in one third of patients, the fatigue prevalence ranges from 23 to 75% due to heterogenous definitions and assessments. Cognitive impairment is found in one third of stroke patients 3-12 months after stroke and the risk for dementia is doubled by the event. Aerobic exercise has been shown to reduce depressive symptoms, counteract fatigue, and improve cognitive functions in non-stroke patients. Furthermore, exercise is known to strengthen the immune system. It is unknown, though, if aerobic exercise can counteract poststroke depression, fatigue, poststroke dementia and poststroke immunosuppression. Therefore, we aim to analyse the effect of aerobic exercise on functional recovery, cognition, emotional well-being, and the immune system. Reorganization of topological networks of the brain shall be visualized by diffusion MRI fibre tracking.</p><p><strong>Methods: </strong>Adults with mild to moderate stroke impairment (initial NIHSS or NIHSS determined at the moment of maximal deterioration 1-18) are recruited within two weeks of stroke onset. Study participants must be able to walk independently without risk of falling. All patients are equipped with wearable devices (smartwatches) measuring the heart rate and daily step count. The optimal heart rate zone is determined by lactate ergometry at baseline. Patients are randomized to the control or the intervention group, the latter performing a heart rate-controlled walking training on own initiative 5 times a week for 45 min. All patients receive medical care and stroke rehabilitation to the usual standard of care. The following assessments are conducted at baseline and after 90 days: Fugl Meyer-assessment for the upper and lower extremity, 6 min-walk test, neuropsychological assessment (cognition: MoCA, SDMT; fatigue and depression: FSMC, HADS-D, participation: WHODAS 2.0 12-items), blood testing (i.e. immune profiling to obtain insights into phenotype and functional features of distinct immune-cell subsets) and cranial magnetic resonance imaging (MRI) with grid-sampled diffusion weighted imaging, white matter fibre tracking and MR spectroscopy.</p><p><strong>Perspective: </strong>This study investigates the effect of smartwatch-controlled aerobic exercise on functional recovery, cognition, emotional well-being, the immune system, and neuronal network reorganization in stroke patients. Trial registration ClinicalTrials.gov NCT Number: NCT05690165. First posted19 January 2023. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT05690165.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2023-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9806961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical surrogates of dysautonomia predict lethal outcome in COVID-19 on intensive care unit. 自律神经失调的临床代用指标可预测重症监护室 COVID-19 患者的死亡结果。
Pub Date : 2023-05-04 DOI: 10.1186/s42466-023-00243-x
Marcel Seungsu Woo, Christina Mayer, Marlene Fischer, Stefan Kluge, Kevin Roedl, Christian Gerloff, Patrick Czorlich, Götz Thomalla, Julian Schulze Zur Wiesch, Nils Schweingruber

Background: Unpredictable vegetative deteriorations made the treatment of patients with acute COVID-19 on intensive care unit particularly challenging during the first waves of the pandemic. Clinical correlates of dysautonomia and their impact on the disease course in critically ill COVID-19 patients are unknown.

Methods: We retrospectively analyzed data collected during a single-center observational study (March 2020-November 2021) which was performed at the University Medical Center Hamburg-Eppendorf, a large tertiary medical center in Germany. All patients admitted to ICU due to acute COVID-19 disease during the study period were included (n = 361). Heart rate variability (HRV) and blood pressure variability (BPV) per day were used as clinical surrogates of dysautonomia and compared between survivors and non-survivors at different time points after admission. Intraindividual correlation of vital signs with laboratory parameters were calculated and corrected for age, sex and disease severity.

Results: Patients who deceased in ICU had a longer stay (median days ± IQR, survivors 11.0 ± 27.3, non-survivors 14.1 ± 18.7, P = 0.85), in contrast time spent under invasive ventilation was not significantly different (median hours ± IQR, survivors 322 ± 782, non-survivors 286 ± 434, P = 0.29). Reduced HRV and BPV predicted lethal outcome in patients staying on ICU longer than 10 days after adjustment for age, sex, and disease severity. Accordingly, HRV was significantly less correlated with inflammatory markers (e.g. CRP and Procalcitonin) and blood carbon dioxide in non-survivors in comparison to survivors indicating uncoupling between autonomic function and inflammation in non-survivors.

Conclusions: Our study suggests autonomic dysfunction as a contributor to mortality in critically ill COVID-19 patients during the first waves of the pandemic. Serving as a surrogate for disease progression, these findings could contribute to the clinical management of COVID-19 patients admitted to the ICU. Furthermore, the suggested measure of dysautonomia and correlation with other laboratory parameters is non-invasive, simple, and cost-effective and should be evaluated as an additional outcome parameter in septic patients treated in the ICU in the future.

背景:在大流行的第一波期间,无法预测的植物神经功能衰退使重症监护室对急性 COVID-19 患者的治疗变得尤为困难。自律神经失调的临床相关性及其对 COVID-19 重症患者病程的影响尚不清楚:我们回顾性分析了一项单中心观察研究(2020 年 3 月至 2021 年 11 月)期间收集的数据,该研究在德国大型三级医疗中心汉堡大学医疗中心(University Medical Center Hamburg-Eppendorf)进行。研究期间,所有因急性 COVID-19 疾病入住重症监护室的患者均被纳入研究范围(n = 361)。每天的心率变异性(HRV)和血压变异性(BPV)被用作自律神经失调的临床替代指标,并在入院后的不同时间点对幸存者和非幸存者进行比较。计算了生命体征与实验室参数的个体内相关性,并根据年龄、性别和疾病严重程度进行了校正:在重症监护室死亡的患者住院时间较长(中位数天数±IQR,幸存者为 11.0 ± 27.3,非幸存者为 14.1 ± 18.7,P = 0.85),相比之下,有创通气时间无显著差异(中位数小时数±IQR,幸存者为 322 ± 782,非幸存者为 286 ± 434,P = 0.29)。在对年龄、性别和疾病严重程度进行调整后,心率变异和血压变异的降低预示着在重症监护室住院超过 10 天的患者的死亡结局。因此,与幸存者相比,非幸存者的心率变异与炎症指标(如 CRP 和降钙素原)和血液二氧化碳的相关性明显较低,这表明非幸存者的自主神经功能与炎症之间没有关联:我们的研究表明,自律神经功能失调是大流行第一波期间 COVID-19 重症患者死亡的原因之一。这些发现可作为疾病进展的替代指标,有助于对入住重症监护室的 COVID-19 患者进行临床管理。此外,所建议的自律神经失调测量方法及其与其他实验室参数的相关性是非侵入性的、简单的和具有成本效益的,今后应将其作为在重症监护室接受治疗的脓毒症患者的附加结果参数进行评估。
{"title":"Clinical surrogates of dysautonomia predict lethal outcome in COVID-19 on intensive care unit.","authors":"Marcel Seungsu Woo, Christina Mayer, Marlene Fischer, Stefan Kluge, Kevin Roedl, Christian Gerloff, Patrick Czorlich, Götz Thomalla, Julian Schulze Zur Wiesch, Nils Schweingruber","doi":"10.1186/s42466-023-00243-x","DOIUrl":"10.1186/s42466-023-00243-x","url":null,"abstract":"<p><strong>Background: </strong>Unpredictable vegetative deteriorations made the treatment of patients with acute COVID-19 on intensive care unit particularly challenging during the first waves of the pandemic. Clinical correlates of dysautonomia and their impact on the disease course in critically ill COVID-19 patients are unknown.</p><p><strong>Methods: </strong>We retrospectively analyzed data collected during a single-center observational study (March 2020-November 2021) which was performed at the University Medical Center Hamburg-Eppendorf, a large tertiary medical center in Germany. All patients admitted to ICU due to acute COVID-19 disease during the study period were included (n = 361). Heart rate variability (HRV) and blood pressure variability (BPV) per day were used as clinical surrogates of dysautonomia and compared between survivors and non-survivors at different time points after admission. Intraindividual correlation of vital signs with laboratory parameters were calculated and corrected for age, sex and disease severity.</p><p><strong>Results: </strong>Patients who deceased in ICU had a longer stay (median days ± IQR, survivors 11.0 ± 27.3, non-survivors 14.1 ± 18.7, P = 0.85), in contrast time spent under invasive ventilation was not significantly different (median hours ± IQR, survivors 322 ± 782, non-survivors 286 ± 434, P = 0.29). Reduced HRV and BPV predicted lethal outcome in patients staying on ICU longer than 10 days after adjustment for age, sex, and disease severity. Accordingly, HRV was significantly less correlated with inflammatory markers (e.g. CRP and Procalcitonin) and blood carbon dioxide in non-survivors in comparison to survivors indicating uncoupling between autonomic function and inflammation in non-survivors.</p><p><strong>Conclusions: </strong>Our study suggests autonomic dysfunction as a contributor to mortality in critically ill COVID-19 patients during the first waves of the pandemic. Serving as a surrogate for disease progression, these findings could contribute to the clinical management of COVID-19 patients admitted to the ICU. Furthermore, the suggested measure of dysautonomia and correlation with other laboratory parameters is non-invasive, simple, and cost-effective and should be evaluated as an additional outcome parameter in septic patients treated in the ICU in the future.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9470435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Competing Interests. 更正竞争利益。
Pub Date : 2023-04-25 DOI: 10.1186/s42466-023-00242-y
{"title":"Correction to Competing Interests.","authors":"","doi":"10.1186/s42466-023-00242-y","DOIUrl":"https://doi.org/10.1186/s42466-023-00242-y","url":null,"abstract":"","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9706927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guideline "Transient Global Amnesia (TGA)" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): S1-guideline. 德国神经病学学会(Deutsche Gesellschaft fr Neurologie)指南“短暂性全局健忘症(TGA)”:s1指南。
Pub Date : 2023-04-20 DOI: 10.1186/s42466-023-00240-0
Dirk Sander, Thorsten Bartsch, Florian Connolly, Christian Enzinger, Urs Fischer, Nils Nellessen, Holger Poppert, Kristina Szabo, Helge Topka

Introduction: In 2022 the DGN (Deutsche Gesellschaft für Neurologie) published an updated Transient Global Amnesia (TGA) guideline. TGA is characterized by a sudden onset of retrograde and anterograde amnesia for a period of one to a maximum of 24 h (with an average of 6 to 8 h). The incidence is estimated between 3 and 8 per 100,000 population/year. TGA is a disorder that occurs predominantly between 50 and 70 years.

Recommendations: The diagnosis of TGA should be made clinically. In case of an atypical clinical presentation or suspicion of a possible differential diagnosis, further diagnostics should be performed immediately. The detection of typical unilateral or bilateral punctate DWI/T2 lesions in the hippocampus (especially the CA1 region) in a proportion of patients proves TGA. The sensitivity of MRI is considered higher when performed between 24 and 72 h after onset. If additional DWI changes occur outside the hippocampus, a vascular etiology should be considered, and prompt sonographic and cardiac diagnostics should be performed EEG may help to differentiate TGA from rare amnestic epileptic attacks, especially in recurrent amnestic attacks. TGA in patients < 50 years of age is a rarity, therefore it is mandatory to rapidly search for other causes in particular in younger patients. The cause of TGA is still unknown. Numerous findings in recent years point to a multifactorial genesis. Because the pathomechanism of TGA is not yet clearly known, no evidence-based therapeutic or prophylactic recommendations can be made.

Conclusions: There is no evidence for chronic sequelae of TGA with respect to cerebral ischemia, chronic memory impairment, or the onset of dementia-related syndromes.

简介:2022年,DGN(德国神经学会)发布了一份更新的瞬态全球失忆(TGA)指南。TGA的特征是突然出现逆行性和顺行性健忘症,持续时间为1至24小时(平均6至8小时)。发病率估计为每年每100000人中有3至8人。TGA是一种主要发生在50至70岁之间的疾病。建议:TGA的诊断应在临床上进行。如果出现非典型临床表现或怀疑可能的鉴别诊断,应立即进行进一步诊断。在一定比例的患者中,在海马体(尤其是CA1区)检测到典型的单侧或双侧点状DWI/T2病变,证明了TGA。当在发病后24至72小时之间进行MRI检查时,MRI的灵敏度被认为更高。如果海马外出现额外的DWI变化,应考虑血管病因,并及时进行超声和心脏诊断。脑电图可能有助于区分TGA和罕见的遗忘性癫痫发作,尤其是在复发性遗忘性发作中。患者TGA 结论:没有证据表明TGA在脑缺血、慢性记忆障碍或痴呆相关综合征发作方面存在慢性后遗症。
{"title":"Guideline \"Transient Global Amnesia (TGA)\" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): S1-guideline.","authors":"Dirk Sander, Thorsten Bartsch, Florian Connolly, Christian Enzinger, Urs Fischer, Nils Nellessen, Holger Poppert, Kristina Szabo, Helge Topka","doi":"10.1186/s42466-023-00240-0","DOIUrl":"10.1186/s42466-023-00240-0","url":null,"abstract":"<p><strong>Introduction: </strong>In 2022 the DGN (Deutsche Gesellschaft für Neurologie) published an updated Transient Global Amnesia (TGA) guideline. TGA is characterized by a sudden onset of retrograde and anterograde amnesia for a period of one to a maximum of 24 h (with an average of 6 to 8 h). The incidence is estimated between 3 and 8 per 100,000 population/year. TGA is a disorder that occurs predominantly between 50 and 70 years.</p><p><strong>Recommendations: </strong>The diagnosis of TGA should be made clinically. In case of an atypical clinical presentation or suspicion of a possible differential diagnosis, further diagnostics should be performed immediately. The detection of typical unilateral or bilateral punctate DWI/T2 lesions in the hippocampus (especially the CA1 region) in a proportion of patients proves TGA. The sensitivity of MRI is considered higher when performed between 24 and 72 h after onset. If additional DWI changes occur outside the hippocampus, a vascular etiology should be considered, and prompt sonographic and cardiac diagnostics should be performed EEG may help to differentiate TGA from rare amnestic epileptic attacks, especially in recurrent amnestic attacks. TGA in patients < 50 years of age is a rarity, therefore it is mandatory to rapidly search for other causes in particular in younger patients. The cause of TGA is still unknown. Numerous findings in recent years point to a multifactorial genesis. Because the pathomechanism of TGA is not yet clearly known, no evidence-based therapeutic or prophylactic recommendations can be made.</p><p><strong>Conclusions: </strong>There is no evidence for chronic sequelae of TGA with respect to cerebral ischemia, chronic memory impairment, or the onset of dementia-related syndromes.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9422207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Beyond treatment of chronic pain: a scoping review about epidural electrical spinal cord stimulation to restore sensorimotor and autonomic function after spinal cord injury. 超越慢性疼痛的治疗:脊髓损伤后硬膜外电刺激恢复感觉运动和自主神经功能的范围综述。
Pub Date : 2023-04-13 DOI: 10.1186/s42466-023-00241-z
Antonia Luz, Rüdiger Rupp, Rezvan Ahmadi, Norbert Weidner

Epidural electrical epinal cord stimulation (ESCS) is an established therapeutic option in various chronic pain conditions. In the last decade, proof-of-concept studies have demonstrated that ESCS in combination with task-oriented rehabilitative interventions can partially restore motor function and neurological recovery after spinal cord injury (SCI). In addition to the ESCS applications for improvement of upper and lower extremity function, ESCS has been investigated for treatment of autonomic dysfunction after SCI such as orthostatic hypotension. The aim of this overview is to present the background of ESCS, emerging concepts and its readiness to become a routine therapy in SCI beyond treatment of chronic pain conditions.

硬膜外电刺激(ESCS)是一种成熟的治疗选择在各种慢性疼痛条件。在过去的十年中,概念验证研究表明,ESCS结合任务导向的康复干预可以部分恢复脊髓损伤(SCI)后的运动功能和神经功能恢复。除了ESCS用于改善上肢和下肢功能外,ESCS还被研究用于治疗脊髓损伤后的自主神经功能障碍,如体位性低血压。本综述的目的是介绍ESCS的背景,新兴概念及其在治疗慢性疼痛之外成为脊髓损伤常规治疗的准备。
{"title":"Beyond treatment of chronic pain: a scoping review about epidural electrical spinal cord stimulation to restore sensorimotor and autonomic function after spinal cord injury.","authors":"Antonia Luz, Rüdiger Rupp, Rezvan Ahmadi, Norbert Weidner","doi":"10.1186/s42466-023-00241-z","DOIUrl":"10.1186/s42466-023-00241-z","url":null,"abstract":"<p><p>Epidural electrical epinal cord stimulation (ESCS) is an established therapeutic option in various chronic pain conditions. In the last decade, proof-of-concept studies have demonstrated that ESCS in combination with task-oriented rehabilitative interventions can partially restore motor function and neurological recovery after spinal cord injury (SCI). In addition to the ESCS applications for improvement of upper and lower extremity function, ESCS has been investigated for treatment of autonomic dysfunction after SCI such as orthostatic hypotension. The aim of this overview is to present the background of ESCS, emerging concepts and its readiness to become a routine therapy in SCI beyond treatment of chronic pain conditions.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2023-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9309428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infective endocarditis and stroke: when does it bleed? A single center retrospective study. 感染性心内膜炎和中风:何时出血?单中心回顾性研究。
Pub Date : 2023-04-06 DOI: 10.1186/s42466-023-00239-7
L Nitsch, O Shirvani Samani, M Silaschi, M Schafigh, S Zimmer, G C Petzold, C Kindler, F J Bode

Background: Infective endocarditis (IE) is a serious condition with a high mortality, represents a rare cause of stroke and an increased risk of intracranial hemorrhage. In this single center study, we characterize stroke patients with IE. We were interested in risk factors for intracranial hemorrhage and outcome of patients with intracranial hemorrhage compared to patients with ischemic stroke.

Methods: Patients with IE and symptomatic ischemic stroke or intracranial hemorrhage admitted to our hospital between January 2019 and December 2022 were included in this retrospective study.

Results: 48 patients with IE and ischemic stroke or intracranial hemorrhage were identified. 37 patients were diagnosed with ischemic stroke, 11 patients were diagnosed with intracranial hemorrhage. The intracranial hemorrhage occurred within the first 12 days after admission. We identified Staphylococcus aureus detection and thrombocytopenia as risk factors for hemorrhagic complications. An increased in-hospital mortality in patients with intracranial hemorrhage (63.6% vs. 22%, p = 0.022) was found, whereas patients with ischemic stroke and patients with intracranial hemorrhage do not differ regarding favorable clinical outcome (27% vs. 27.3%, p = 1.0). 27.3% patients with intracranial hemorrhage and 43.2% patients with ischemic stroke underwent cardiac surgery. Overall, 15.7% new ischemic strokes occurred after valve reconstruction, whereas no new intracranial hemorrhage was observed.

Conclusions: We found an increased in-hospital mortality in patients with intracranial hemorrhage. Beside thrombocytopenia, we identified S. aureus detection as a risk factor for intracranial hemorrhage.

背景:感染性心内膜炎(IE)是一种严重的疾病,死亡率高,是中风的罕见原因,颅内出血的风险增加。在这项单中心研究中,我们对脑卒中患者的IE进行了表征。我们对颅内出血的危险因素和颅内出血患者与缺血性脑卒中患者的预后感兴趣。方法:选取2019年1月至2022年12月在我院住院的IE合并有症状的缺血性脑卒中或颅内出血患者进行回顾性研究。结果:48例IE合并缺血性脑卒中或颅内出血。37例诊断为缺血性脑卒中,11例诊断为颅内出血。颅内出血发生在入院后12天内。我们确定金黄色葡萄球菌检测和血小板减少是出血并发症的危险因素。颅内出血患者的住院死亡率增加(63.6%对22%,p = 0.022),而缺血性卒中患者和颅内出血患者在良好的临床结果方面没有差异(27%对27.3%,p = 1.0)。27.3%的颅内出血患者和43.2%的缺血性脑卒中患者行心脏手术。总体而言,15.7%的新缺血性脑卒中发生在瓣膜重建后,而没有观察到新的颅内出血。结论:我们发现颅内出血患者的住院死亡率增加。除了血小板减少症,我们发现金黄色葡萄球菌检测是颅内出血的危险因素。
{"title":"Infective endocarditis and stroke: when does it bleed? A single center retrospective study.","authors":"L Nitsch,&nbsp;O Shirvani Samani,&nbsp;M Silaschi,&nbsp;M Schafigh,&nbsp;S Zimmer,&nbsp;G C Petzold,&nbsp;C Kindler,&nbsp;F J Bode","doi":"10.1186/s42466-023-00239-7","DOIUrl":"https://doi.org/10.1186/s42466-023-00239-7","url":null,"abstract":"<p><strong>Background: </strong>Infective endocarditis (IE) is a serious condition with a high mortality, represents a rare cause of stroke and an increased risk of intracranial hemorrhage. In this single center study, we characterize stroke patients with IE. We were interested in risk factors for intracranial hemorrhage and outcome of patients with intracranial hemorrhage compared to patients with ischemic stroke.</p><p><strong>Methods: </strong>Patients with IE and symptomatic ischemic stroke or intracranial hemorrhage admitted to our hospital between January 2019 and December 2022 were included in this retrospective study.</p><p><strong>Results: </strong>48 patients with IE and ischemic stroke or intracranial hemorrhage were identified. 37 patients were diagnosed with ischemic stroke, 11 patients were diagnosed with intracranial hemorrhage. The intracranial hemorrhage occurred within the first 12 days after admission. We identified Staphylococcus aureus detection and thrombocytopenia as risk factors for hemorrhagic complications. An increased in-hospital mortality in patients with intracranial hemorrhage (63.6% vs. 22%, p = 0.022) was found, whereas patients with ischemic stroke and patients with intracranial hemorrhage do not differ regarding favorable clinical outcome (27% vs. 27.3%, p = 1.0). 27.3% patients with intracranial hemorrhage and 43.2% patients with ischemic stroke underwent cardiac surgery. Overall, 15.7% new ischemic strokes occurred after valve reconstruction, whereas no new intracranial hemorrhage was observed.</p><p><strong>Conclusions: </strong>We found an increased in-hospital mortality in patients with intracranial hemorrhage. Beside thrombocytopenia, we identified S. aureus detection as a risk factor for intracranial hemorrhage.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9252993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood pressure management in ischemic stroke patients undergoing mechanical thrombectomy. 缺血性脑卒中机械取栓术患者的血压管理。
Pub Date : 2023-03-30 DOI: 10.1186/s42466-023-00238-8
Michael De Georgia, Theodore Bowen, K Rose Duncan, Alex Bou Chebl

The relationship between presenting blood pressure in acute ischemic stroke patients and outcome is complex. Several studies have demonstrated a U-shaped curve with worse outcomes when blood pressure is high or low. The American Heart Association/American Stroke Association guidelines recommend values of blood pressure < 185/110 mmHg in patients treated with intravenous t-PA and "permissive hypertension" up to 220/120 mmHg in those not treated with intravenous t-PA. The optimal blood pressure target is less clear in patients undergoing mechanical thrombectomy. Before thrombectomy, the guidelines recommend a blood pressure < 185/110 mmHg though patients with even lower systolic blood pressures may have better outcomes. During and after thrombectomy, the guidelines recommend a blood pressure < 180/105 mmHg. However, several studies have suggested that during thrombectomy the primary goal should be to prevent significant low blood pressure (e.g., target systolic blood pressure > 140 mmHg or MAP > 70 mmHg). After thrombectomy, the primary goal should be to prevent high blood pressure (e.g., target systolic blood pressure < 160 mmHg or MAP < 90 mmHg). To make more specific recommendations, large, randomized-control studies are needed that address factors such as the baseline blood pressure, timing and degree of revascularization, status of collaterals, and estimated risk of reperfusion injury.

急性缺血性脑卒中患者的血压与预后之间的关系是复杂的。一些研究表明,当血压高或低时,u型曲线的结果更差。美国心脏协会/美国卒中协会指南建议血压值为140 mmHg或MAP > 70 mmHg)。取栓后,首要目标是预防高血压(如目标收缩压)
{"title":"Blood pressure management in ischemic stroke patients undergoing mechanical thrombectomy.","authors":"Michael De Georgia,&nbsp;Theodore Bowen,&nbsp;K Rose Duncan,&nbsp;Alex Bou Chebl","doi":"10.1186/s42466-023-00238-8","DOIUrl":"https://doi.org/10.1186/s42466-023-00238-8","url":null,"abstract":"<p><p>The relationship between presenting blood pressure in acute ischemic stroke patients and outcome is complex. Several studies have demonstrated a U-shaped curve with worse outcomes when blood pressure is high or low. The American Heart Association/American Stroke Association guidelines recommend values of blood pressure < 185/110 mmHg in patients treated with intravenous t-PA and \"permissive hypertension\" up to 220/120 mmHg in those not treated with intravenous t-PA. The optimal blood pressure target is less clear in patients undergoing mechanical thrombectomy. Before thrombectomy, the guidelines recommend a blood pressure < 185/110 mmHg though patients with even lower systolic blood pressures may have better outcomes. During and after thrombectomy, the guidelines recommend a blood pressure < 180/105 mmHg. However, several studies have suggested that during thrombectomy the primary goal should be to prevent significant low blood pressure (e.g., target systolic blood pressure > 140 mmHg or MAP > 70 mmHg). After thrombectomy, the primary goal should be to prevent high blood pressure (e.g., target systolic blood pressure < 160 mmHg or MAP < 90 mmHg). To make more specific recommendations, large, randomized-control studies are needed that address factors such as the baseline blood pressure, timing and degree of revascularization, status of collaterals, and estimated risk of reperfusion injury.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9269264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Stroke thrombolysis or not for an intraventricular thrombus. 脑室内血栓是否可以溶栓。
Pub Date : 2023-03-20 DOI: 10.1186/s42466-023-00235-x
Josef Finsterer, Sounira Mehri
{"title":"Stroke thrombolysis or not for an intraventricular thrombus.","authors":"Josef Finsterer,&nbsp;Sounira Mehri","doi":"10.1186/s42466-023-00235-x","DOIUrl":"https://doi.org/10.1186/s42466-023-00235-x","url":null,"abstract":"","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9524878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author response to "Stroke thrombolysis or not for an intraventricular thrombus". 作者对“脑室内血栓是否溶栓”的回应。
Pub Date : 2023-03-20 DOI: 10.1186/s42466-023-00236-w
Dimitrios Tsiptsios
{"title":"Author response to \"Stroke thrombolysis or not for an intraventricular thrombus\".","authors":"Dimitrios Tsiptsios","doi":"10.1186/s42466-023-00236-w","DOIUrl":"https://doi.org/10.1186/s42466-023-00236-w","url":null,"abstract":"","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9524881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telestroke networks for area-wide access to endovascular stroke treatment. 远程卒中网络,为整个地区提供血管内卒中治疗。
Pub Date : 2023-03-03 DOI: 10.1186/s42466-023-00237-9
Hans Worthmann, S Winzer, R Schuppner, C Gumbinger, J Barlinn

Background: Endovascular therapy (EVT) offers a highly effective therapy for patients with acute ischemic stroke due to large vessel occlusion. Comprehensive stroke centers (CSC) are required to provide permanent accessibility to EVT. However, when affected patients are not located in the immediate catchment area of a CSC, i.e. in rural or structurally weaker areas, access to EVT is not always ensured.

Main body: Telestroke networks play a crucial role in closing this healthcare coverage gap and thereby support specialized stroke treatment. The aim of this narrative review is to elaborate the concepts for the indication and transfer of EVT candidates via telestroke networks in acute stroke care. The targeted readership includes both comprehensive stroke centers and peripheral hospitals. The review is intended to identify ways to design care beyond those areas with narrow access to stroke unit care to provide the indicated highly effective acute therapies on a region-wide basis. Here, the two different models of care: "mothership" and "drip-and-ship" concerning rates of EVT and its complications as well as outcomes are compared. Decisively, forward-looking new model approaches such as a third model the "flying/driving interentionalists" are introduced and discussed, as far as few clinical trials have investigated these approaches. Diagnostic criteria used by the telestroke networks to enable appropriate patient selection for secondary intrahospital emergency transfers are displayed, which need to meet the criteria in terms of speed, quality and safety.

Conclusion: The few findings from the studies with telestroke networks are neutral for comparison in the drip-and-ship and mothership models. Supporting spoke centres through telestroke networks currently seems to be the best option for offering EVT to a population in structurally weaker regions without direct access to a CSC. Here, it is essential to map the individual reality of care depending on the regional circumstances.

背景:血管内治疗(EVT)为大血管闭塞导致的急性缺血性卒中患者提供了一种高效的治疗方法。需要综合卒中中心(CSC)来提供永久性的 EVT 治疗。然而,如果患者不在综合卒中中心的邻近地区,如农村或结构薄弱地区,则无法始终确保获得 EVT 治疗:主要内容:远程卒中网络在缩小医疗覆盖面差距方面发挥着至关重要的作用,从而为卒中的专业治疗提供支持。本综述旨在阐述在急性卒中治疗中通过远程卒中网络进行 EVT 的适应症和转移的概念。读者对象包括综合性卒中中心和外围医院。本综述旨在确定如何在卒中单元治疗范围较窄的地区之外设计治疗方案,以便在整个地区范围内提供所指示的高效急性期疗法。这里有两种不同的治疗模式:"母船 "和 "点滴加母船 "两种不同的护理模式在 EVT 及其并发症的发生率和治疗效果方面进行了比较。由于很少有临床试验对这些方法进行研究,因此果断地引入并讨论了前瞻性的新模式方法,如第三种模式 "飞行/驾驶跨学科者"。此外,还介绍了远程中风网络所使用的诊断标准,以便为院内二次紧急转运选择合适的病人,这些标准需要在速度、质量和安全方面达到要求:结论:远程卒中网络的研究结果为数不多,但在滴注-船模式和母船模式的比较中具有中立性。目前,通过远程卒中网络支持转运中心似乎是在结构薄弱地区为无法直接进入社区服务中心的人群提供 EVT 的最佳选择。在这种情况下,必须根据地区的具体情况,制定具体的治疗方案。
{"title":"Telestroke networks for area-wide access to endovascular stroke treatment.","authors":"Hans Worthmann, S Winzer, R Schuppner, C Gumbinger, J Barlinn","doi":"10.1186/s42466-023-00237-9","DOIUrl":"10.1186/s42466-023-00237-9","url":null,"abstract":"<p><strong>Background: </strong>Endovascular therapy (EVT) offers a highly effective therapy for patients with acute ischemic stroke due to large vessel occlusion. Comprehensive stroke centers (CSC) are required to provide permanent accessibility to EVT. However, when affected patients are not located in the immediate catchment area of a CSC, i.e. in rural or structurally weaker areas, access to EVT is not always ensured.</p><p><strong>Main body: </strong>Telestroke networks play a crucial role in closing this healthcare coverage gap and thereby support specialized stroke treatment. The aim of this narrative review is to elaborate the concepts for the indication and transfer of EVT candidates via telestroke networks in acute stroke care. The targeted readership includes both comprehensive stroke centers and peripheral hospitals. The review is intended to identify ways to design care beyond those areas with narrow access to stroke unit care to provide the indicated highly effective acute therapies on a region-wide basis. Here, the two different models of care: \"mothership\" and \"drip-and-ship\" concerning rates of EVT and its complications as well as outcomes are compared. Decisively, forward-looking new model approaches such as a third model the \"flying/driving interentionalists\" are introduced and discussed, as far as few clinical trials have investigated these approaches. Diagnostic criteria used by the telestroke networks to enable appropriate patient selection for secondary intrahospital emergency transfers are displayed, which need to meet the criteria in terms of speed, quality and safety.</p><p><strong>Conclusion: </strong>The few findings from the studies with telestroke networks are neutral for comparison in the drip-and-ship and mothership models. Supporting spoke centres through telestroke networks currently seems to be the best option for offering EVT to a population in structurally weaker regions without direct access to a CSC. Here, it is essential to map the individual reality of care depending on the regional circumstances.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2023-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10820740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurological Research and Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1